ClinicalTrials.gg
RecruitingNCT06584617Updated Sep 5, 2024

The Purpose of This Study is to Assess Clinical Efficacy and Safety of Berovenal® Intended to Promote Treatment and to Expedite Chronic Diabetic Foot Ulcer Healing

An interventional study of Berovenal® and NU-GEL Hydrogel with Alginate in Diabetic Foot Ulcer, sponsored by VULM s.r.o.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by VULM s.r.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled May 2023, registered Aug 2024).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetic Foot with a site in Poland — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetic Foot · Poland.

Planned enrollment
14th of 19
66 · median 159
Started
2023
with 1 other
No phase
5 of 20
1 open now
Registered
18th of 20
by date

Among the 20 studies in Diabetic Foot with a site in Poland, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 with no phase, and was the 18th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

3 of the 20 studies in Diabetic Foot with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetic Foot with a site in Poland, or all of them as a file.
02

Study summary

The goal of this clinical investigation is to evaluate clinical efficacy of medical device Berovenal® intended to promote treatment and to expedite healing of chronic diabetic foot ulcer in male or female subjects aged 18-85 years with diabetes mellitus (type 1 or 2) and with present diabetic foot ulcer by providing moist environment similar to intracellular environment of the damaged tissue. It will also learn about the safety of medical device Berovenal®.

The main questions it aims to answer are:

  • Does medical device Berovenal® lower the size of diabetic foot ulcer?
  • What medical problems do participants have when using medical device Berovenal®?

Researchers will compare medical device Berovenal® to a reference device (device with similar purpose of use).

Participants will:

  • Use medical device Berovenal® or a reference device every day for 8 weeks or to the time point when the diabetic foot is closed
  • Visit the clinic once every 2 weeks for checkups and tests
  • Keep a diary of their symptoms and the number of times they use medical device Berovenal® or a reference device
03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male, or female subjects aged 18-85 years;
  • diabetes mellitus (type 1 or 2) documented at least 12 months prior to Visit 1;
  • presence of a diabetic foot ulcer meeting the following criteria (Index ulcer):

    • grade 1 or 2 according to the Wagner classification;
    • if applicable, surgically debrided ≥ 7 days prior to Visit 1;
    • at the time of randomisation:
  • sized 1 - 25 cm2;
  • present for ≥ 14 days;
  • offloaded for ≥ 7 days;
  • not infected.
  • ≤ 10% (DCCT) or 85.8 mmol/mol (IFCC) at Visit 1;
  • willing and able to comply with the scheduled procedures;
  • legally capable, able to understand the provided information and willing to sign the form.

Exclusion criteria

Exclusion Criteria:

  • known for application of hydrogel dressings, incl. Berovenal® and NU-GEL Hydrogel with Alginate;
  • at the time of randomisation - documented reduction in Index ulcer area by > 20%, as compared to its size at Visit 1;
  • Index ulcer primarily caused by a medical condition other than diabetes mellitus;
  • inadequate arterial circulation to the foot documented within 28 days prior to Visit 1, or during the screening period:

    • Ankle-brachial Index \< 0.7 or > 1.3 and/or
    • Toe-brachial Index \< 0.7;
  • presence of acute Charcot's neuro-arthropathy, or osteomyelitis, on the affected foot within 3 months prior to Visit 1;
  • use of wound dressings that include growth factors, bioengineered tissues, or skin substitutes within 14 days prior to Visit 1, or documented intention to use them during the subject's participation;
  • use of any drug(s) or device(s), systemic treatment (including systemic ), or application of topical steroids to the Index ulcer surface, within 28 days prior to Visit 1;
  • use of cytotoxic chemotherapy and/or radiotherapy within 6 months prior to Visit 1;
  • known history of bone cancer or disease of the affected limb;
  • poor nutritional status;
  • presence of an on-going uncontrolled renal, hepatic, cardiovascular or other disease that could pose an additional risk for the participant, or could significantly influence interpretation of the results (as evaluated by the investigator);
  • known history of non-compliance and/or presence of any condition(s) seriously compromising the subject's ability to adhere to the procedures required by this Clinical Investigational Plan;
  • pregnant or breast-feeding females;
  • females of not using an effective method of .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Berovenal®

    Device: Berovenal®

  • Active comparator
    NU-GEL Hydrogel with Alginate

    Device: NU-GEL Hydrogel with Alginate

Interventions

  • DeviceBerovenal®

    Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.

  • DeviceNU-GEL Hydrogel with Alginate

    Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.

06

What researchers measure

Primary outcomes

  1. Evaluation of clinical efficacy based on comparison of the percentage reduction in Index ulcer area.

    Time frame: 8 weeks

Secondary outcomes

  1. Evaluation of clinical efficacy based on proportion of subjects who achieved complete closure of Index ulcers

    Time frame: 8 weeks

  2. Evaluation of clinical efficacy based on median time until complete Index ulcer closure

    Time frame: 8 weeks

  3. Evaluation of clinical efficacy based on proportion of subjects who achieved a reduction in the Index ulcer area by ≥ 80%

    Time frame: 4, 6 and 8 weeks

  4. Evaluation of clinical efficacy based on mean percentage change of the Index ulcer area

    Time frame: 2, 4, 6 and 8 weeks

  5. Evaluation of clinical efficacy based on improvement in the subject's reported quality of life assessed by the Wound-QoL

    Time frame: 2, 4, 6 and 8 weeks

  6. Evaluation of safety based on proportion of target wounds with a documented wound infection

    Time frame: 8 weeks

  7. Evaluation of safety occurrence of adverse events, device failures or complaints

    Time frame: 8 weeks

  8. Evaluation of clinical efficacy based on wound healing process

    The analysis will inolve evaluation wound depth, presence of granulation tissue, exsudate and infection at individual time points.

    Time frame: 2, 4, 6 and 8 weeks

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2025, 22 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 22 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 5, 2024
StartActual
May 17, 2023
Primary completionEst.
Mar 2025
CompletionEst.
Dec 2025
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06584617
Lead sponsor
VULM s.r.o.
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Sep 5, 2024
Start date
May 17, 2023
Primary completion
Mar 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Sep 5, 2024

Study contacts

Marianna Forgáčová
Contact
regulatory@vulm.sk
+421 918 415 585
Juraj Keszegh
Contact
juraj.keszegh@gmail.com
+421 904 967 555

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion